Top Line: Are induction tremelimumab and durvalumab safe induction therapy in patients planned to receive chemoradiation for locally advanced NSCLC?
The Study: After the success of adding maintenance immunotherapy to chemoradiation for locally advanced NSCLC, multiple trials have explored either induction or concurrent immunotherapy. However, many of these have found excess toxicity when immunotherapy is given before or during chemoradiation. In this phase 1 trial, 15 patients planned to receive CRT for unresectable stage II/III NSCLC were treated with induction tremelimumab plus durvalumab prior to CRT. Three different dose cohorts were used including a low dose tremelimumab arm and two high dose tremelimumab arms. The low dose cohort met safety criteria while the two high dose arms did not. Grade 3+ immune-related toxicity was seen in 47%, of which 6 out of 7 patients received high dose tremelimumab. Most patients (73%) with N2/3 disease were downstaged to N0-2 after induction immunotherapy.
TBL: In this small, phase 1 study, combination tremelimumab and durvalumab prior to chemoradiation resulted in excess grade 3+ toxicity in patients with locally advanced NSCLC. | Smeenk, Clin Cancer Res 2025
The Study: After the success of adding maintenance immunotherapy to chemoradiation for locally advanced NSCLC, multiple trials have explored either induction or concurrent immunotherapy. However, many of these have found excess toxicity when immunotherapy is given before or during chemoradiation. In this phase 1 trial, 15 patients planned to receive CRT for unresectable stage II/III NSCLC were treated with induction tremelimumab plus durvalumab prior to CRT. Three different dose cohorts were used including a low dose tremelimumab arm and two high dose tremelimumab arms. The low dose cohort met safety criteria while the two high dose arms did not. Grade 3+ immune-related toxicity was seen in 47%, of which 6 out of 7 patients received high dose tremelimumab. Most patients (73%) with N2/3 disease were downstaged to N0-2 after induction immunotherapy.
TBL: In this small, phase 1 study, combination tremelimumab and durvalumab prior to chemoradiation resulted in excess grade 3+ toxicity in patients with locally advanced NSCLC. | Smeenk, Clin Cancer Res 2025

